Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal...
Solidion Technology Awarded A Second Grant From The U.S. Department of Energy For Nuclear Reactors
Grant Proceeds Will Accelerate Research Into Anti-Corrosive Additives in Molten-Salts-Based Heat Transfer Fluids For Nuclear Reactors. DALLAS, Dec. 29, 2025 /PRNewswire/ -- Solidion Technology Inc. ("Solidion" or the "Company") (Nasdaq: STI), an...
CGTN: Why China's anti-corruption drive never stops
CGTN published an article on China's ongoing anti-corruption campaign. The article explains how China's approach differs from Western models, highlights strict Party self-governance, and emphasizes that anti-corruption efforts ultimately serve the...
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its...
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion...
China's Capital Market Builds Momentum Toward a Resilient "Slow Bull"
SHENZHEN, China, Dec. 19, 2025 /PRNewswire/ -- Guosen Securities Co., Ltd., one of China's leading comprehensive investment banks and securities firms, observes that the country's capital market is entering a new phase of stability and resilience,...
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody,...
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has...
Rare Rolex Reference 4113 Split-Seconds Chronograph to Headline FutureGrail Online Auction
SINGAPORE, Nov. 4, 2025 /PRNewswire/ -- FutureGrail today announced that the Rolex Reference 4113 "anti-magnetic" split-seconds chronograph (serial number 051 319) in its collection will headline the firm's online auction (8–14 November, 2025)....
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today...